ACADIA PHARMACEUTICALS INC. Unrealized Gain (Loss) on Securities
ACADIA PHARMACEUTICALS INC. (ACAD) reported Unrealized Gain (Loss) on Securities of $45.00 thousand for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-27.
Discontinued › Income Statement › Other Income
us-gaap:UnrealizedGainLossOnSecurities · last filed 2014-02-27
- ACADIA PHARMACEUTICALS INC. unrealized gain (loss) on securities for the quarter ending 2013-12-31 was -$35.00K.
- ACADIA PHARMACEUTICALS INC. unrealized gain (loss) on securities for the quarter ending 2012-12-31 was $0.00.
- ACADIA PHARMACEUTICALS INC. unrealized gain (loss) on securities for fiscal 2013 was $45.00K.
- ACADIA PHARMACEUTICALS INC. unrealized gain (loss) on securities for fiscal 2012 was -$4.00K, a 144.44% decline from fiscal 2011.
- ACADIA PHARMACEUTICALS INC. unrealized gain (loss) on securities for fiscal 2011 was $9.00K.
| Period end | Unrealized Gain (Loss) on Securities 3 month | Unrealized Gain (Loss) on Securities 9 month | Unrealized Gain (Loss) on Securities 12 month |
|---|---|---|---|
| 2013-12-31 | -$35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $45.00K 10-K · filed 2014-02-27 | |
| 2013-09-30 | $80.00K 10-Q · filed 2013-11-06 | ||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | -$4.00K 10-K · filed 2014-02-27 | |
| 2012-09-30 | -$4.00K 10-Q · filed 2013-11-06 | ||
| 2011-12-31 | $9.00K 10-K · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |